LifePak Wysokiej jakości suplement zawierający pełny zestaw wielu składników odżywczych Podsumowanie



Pobieranie 211.12 Kb.
Strona4/5
Data07.05.2016
Rozmiar211.12 Kb.
1   2   3   4   5

  • Lyle B. J., Mares-Perlman J. A., Klein B. E. K., Klein R., Greger J. L., Antioxidant intake and risk of incident age-related nulear cataracts in the Beaver Dam Eye Study, Am. J. Epidemiol., 1999; 149:801-9

  • Manson J. E., Gaziano J. M., Jonas M. A., Hennekens C. H., Antioxidants and cardiovascular disease: a review, J. Am. Coll. Nutr., 1993; 12: 426-32

  • Gey K. F., Vitamins E plus C and interacting conutrients required for optimal health, BioFactors, 1998; 7: 113-74

  • Anderson J. W., Gowri M. S., Turner J., et al., Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabets mellitus, J. Am. Coll. Nutr., 1999; 18: 451-61

  • Mosca L., Rubenfire M., Mandel C., et al., Antioxidant nutrient supplementation reduces the susceptibility of low-density lipoprotein to oxidation in patients with coronary artery disease, J. Am. Coll. Cardiol., 1997; 30: 392-9

  • Stamfer M. J., Rimm E. B., Epidemiological evidence for vitamin E in prevention of cariovascular disease, Am. J. Clin. Nutr., 1995; 62: 1365S-9S

  • Spencer A. P., Carson D. S., Crouch M. A., Vitamin E and coronary artery disease, Arch. Intern. Med., 1999; 159: 1313-20

  • Stephens N. G., Parsons A., Schofield P. M., Kelly F., Cheeseman K., Mitchinson M. J., Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS), Lancet, 1996; 347: 781-6

  • Chan A. C., Vitamin E and atherosclerosis, J. Nutr., 1998; 128: 1593-6

  • Simons L. A., von Konigsmark M., Balasubramaniam S., What dose of vitamin E is required to reduce susceptibility of LDL to oxidation?, Aust. N. Z. J. Med., 1996; 26: 496-503

  • Princen H. M., van Duyvenvoorde W., Buytenhek R., et al., Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women, Arterioscler. Thromb. Vasc. Biol., 1995; 15: 325-33

  • Calzada C., Brucdorfer K. R., Rice-Evans C. A., The influence of antioxidant nutrients on platelet function in healthy volunteers, Atherosclerosis, 1997; 128: 97-105

  • Azen S. P., Qian D. J., Mack W. J., et al., Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering, Circulation, 1996; 94: 2369-72

  • Davey P. J., Schultz M., Gliksman M., Dobson M., Aristides M., Stephens N. G., Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial), Am. J. Cardiol., 1998; 82: 414-7

  • Mottram P., Shige H., Nestel P., Vitamin E improves arterial compliance in middle-aged men and women, Atheriosclerosis, 1999; 145: 399-404

  • Acuff R. V., Thedford S. S., Hidiroglou N. N., Papas A. M., Odom Jr. T. A., Relative bioavailability of RRR- and all-rac-α-tocopheryl acetate in humans: studies using deuterated compounds, Am. J. Clin. Nutr., 1994; 60: 397-402

  • Ferslew K. E., Acuff R. V., Daigneault E. A., Wooley T. W., Stanton P. E. J., Pharmacokinetics and bioavailability of the RRR and all racemic stereoisomers of alpha-tocopherol in humans after single oral administration, J. Clin. Pharmacol., 1993; 33: 84-8

  • Burton G. W., Traber M. G., Acuff R. V., Walters D. N., Kayden H., Hughes L., Ingold K. U., Human palsma abd tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E, Am. J. Clin. Nutr., 1998; 67(4): 669-684

  • Chopra R. K., Bhagavan H. N., Relative bioavailabilities of natural and synthetic vitamin E formulations containing mixed tocopherols in human subjects.
    Int. J. Vitam. Nutr. Res., 1999; 69(2): 92-5

  • Fauteck J. D., Schmidt H., Lerchl A., Kurlemann G., Wittkowski W., Malatonin in epilepsy: First results of replacement therapy and first clinical results, Biol. Signals, 1999; 8: 105-10

  • Bendlich A., Langseth L., The health effects of vitamin C supplementation: A review, J. Am. Coll. Nutr., 1995; 14: 124-36

  • Carr A. C., Zhu B. Z., Frei B., Potential antiatherogenic mechanisms of ascorbate (vitamin C) and α-tocopherol (vitamin E), Circ. Res., 2000; 87: 349-54

  • Jacob R. A., Vitamin C nutriture and risk of atherosclerotic heart disease, Nutrition reviews, 1998; 56: 334-7

  • Niki E., Noguchi N., Tsuchihashi H., Gotoh N., Interaction among vitamin C, vitamin E, and beta-carotene, Am. J. Clin. Nutr., 1995; 62: 1322S-6S

  • Tanaka K., Hashimoto T., Tokumaru S., Iguchi H., Kojo S., Interactions between vitamin C and vitamin E are observed in tissues of inherently scorbutic rats, J. Nutr., 1997; 127: 2060-4

  • Fuller C. J., Grundy S. M., Norkus E. P., Jialal I., Effect of ascorbate supplementation on low-density lipoprotein oxidation in smokers, Atherosclerosis, 1996; 119: 139-50

  • Fotherby M. D., Williams J. C., Craner P., Ferns G. A., Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons, J. Hypertens., 2000; 18: 411-5

  • Jacques P. F., Effects of vitamin C on high-density lipoprotein cholesterol and blood pressure, J. Am. Coll. Nutr., 1992; 11: 139-44

  • Ness A. R., Khaw K. T., Bingham S., Day N. E., Vitamin C status and blood pressure, J. Hypertens., 1886; 14: 503-8

  • Ness A. R., Chee D., Elliott P., Vitamin C and blood pressure – an overview, J. Hum. Hypertens., 1997; 11: 343-50

  • Salonen J. T., Salonen R., Ihanainen M. et al., Vitamin C deficiency and low linolenate intake associated with elevated blood pressure: the Kuopio Ischemic Heart Disease Risk Factor Study, J. Hypertens. Suppl., 1987; 5: S521-4

  • Tofler G. H., Stec J. J., Stubbe. I., et al., The effect of vitamin C supplementation on coagulatibility and lipid levels in healthy male subjects, Thrombosis Research, 2000; 100: 35-41

  • Kaufmann P. A., Gnechi-Ruscone T., Di Terlizzi M., Schäfers K. P., Lüscher T. F., Camici P. G., Coronary heart disease in smokers – Vitamin C restores coronary microcirculatory function., Circulation, 2000; 102: 1233-8

  • Gokce N., Keancy J. F. Jr., Frei B., et al., Long-term ascorbic acid administration reverses endithelial vasomotor dysfunction in patients with coronary artery disease, Circulation, 1999; 101: 342-6

  • Hiral N., Kawano H., Hirashima O., et al., Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C, Am. J. Physiol. Heart Circ. Physiol., 2000; 279: H1172-H1178

  • Hirashima O., Kawano H., Motoyama T., et al., Improvement of endiothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina – Possible role of reactive oxygen species, J. Am. Coll. Cardiol., 2000: 35: 1860-6

  • Levine G. N., Frei B., Koulouris S. N., Gerhard M. D., Keancy J. F. J., Vita J. A., Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease, Circulation, 1996; 93: 1107-13

  • Watanabe H., Kakihana M., Ohtsuka S., Sugishita Y., Randomized, double-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance, J. Am. Coll. Cardiol., 1998; 31: 1323-9

  • Weber C., Erl W., Weber K., Weber P. C., Increased adhesivenes of isolated monocytes to endothelium is prevented by vitamin C intake in smokers, Circulation, 1996; 93: 1488-92

  • Wilkinson I. B., Megson I. L., MacCallum H., Sogo N., Cockroft J. R., Webb D. J., Oral vitamin C reduces arterial stiffness and platelet aggregation in humans, J. Cardiovasc. Pharmacol., 1999; 34: 690-3

  • Gale C. R., Martyn C. N., Winter P. D., Cooper C., Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people, Br. Med. J., 1995; 310: 1563-6

  • Simon J. A., Hudes E. S., Browner W. S., Serum ascorbic acid and cardiovascular disease prevalance in U.S. adults, Epidemiology, 1998; 9: 316-21

  • Nyyssönen K., Parvianen M. T., Salonen R., Tuomilchto J., Salonen J. T., Vitamni C deficiency and risk of myocardial infarction: Prospective population study of men from eastern Finland, Bmj., 1997; 314: 634-8

  • Knekt P. Reunanen A., Järvinen R., et al., Antioxidant vitamin intake and coronary mortality in a longitudional population study, Am. J. Epidemiol., 1994; 139: 1180-9

  • Enstrom J. E., Kanim L. E., Klein M. A., Vitamin C intake and mortality among a sample of the U.S. population, Epidemiology, 1992; 3: 194-202

  • Levine M. Conry-Cantilena C., Wang Y. et al., Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommened dietary allowance, Proc. Natl. Acad. Sci. U.S.A., 1996; 93: 3704-9

  • Graumlich J. F., Ludden T. M., Conry-Cantilena C., Cantilena L. R., Wang Y. H., Levine M., Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion, Pharm. Res., 1997; 14: 1133-9

  • Lachance P., Dietary intake of carotenes and the carotene gap, Clin. Nutr., 1988; 7: 118-22

  • Kohlmeier L., Hastings S. B., Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention, Am. J. Clin. Nutr., 1995; 62: 1370S-6S

  • Kritchevsky S. B., β-carotene, carotenoids, and the prevention of coronary heart disease, J. Nutr., 1999; 129: 5-8

  • Morris D. L., Ktitchevsky S. B., Davis C. E., Serum carotenoids and coronary heart disease: the Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study, JAMA, 1994; 272: 1439-41

  • Hennekens C. H., Buring J. E., Manson J. E., et al., Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease, N. Engl. J. Med., 1996; 334: 1145-9

  • Kritchevsky S. B., Tell G. S., Shimakawa T., et al., Provitamin A carotenoid intake and carotid artery plaques: the Atherosclerosis Risk in Communities Study, Am. J. Clin. Nutr., 1998; 68: 726-33

  • Arab L., Steck S., Lycopene and cariovascular disease, Am. J. Clin. Nutr., 2000; 71: 1691S-5S

  • Rao A. V. R., Agarwal S., Role of antioxidant lycopene in cancer and heart disease, J. Am. Coll. Nutr., 2000; 19: 563-9

  • Agarwal S., Rao A. V., Tomato lycopene and low-density lipoprotein oxidation: A human dietary study, Lipids, 1998; 33: 981-4

  • Chopra M., O’Neill M. E., Keogh N., Wortley G., Southon S., Thurnham D. I., Influence of incresed fruit and vegetable intake on plasm and lipoprotein carotenoids and LDL oxidation in smokers and nonsmokers, Clinical Chemistry, 2000; 46: 1818-29

  • D’Odorico A., Martines D., Kiechl S. et al., High plasm levels of α- and β-carotene are associated with a lower risk of atherosclerosis – Results from the Bruneck study, Atherosclerosis, 2000; 153: 231-9

  • Kontush A., Spranger T., Reich A., Baum K., Beisiegel U., Lipophilic antioxidants in blood plasma as marker of atherosclerosis: the role of α-carotene and gamma-tocopherol, Atherosclerosis, 1999; 144: 117-22

  • Irbarren C., Folsom A. R., Jacobs D. R. Jr., Gross M. D., Belcher J. D., Eckfeldt J. H., Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis – A case-controlled study, Arterioscler. Thromb. Vasc. Biol., 1997; 17: 1171-7

  • Suter P. M., Effect of vitamin E, vitamin C, and β-carotene on stroke risk, Nutrition reviews, 2000; 58: 184-7

  • Bravo L., Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance, Nutrition reviews, 1998; 56: 317-33

  • Hertog M. G., Feskens E. J., Hollman P. C., Katan M. B., Kromhout D., Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study, Lancet, 1993; 342: 1007-11

  • Hertog M. G., Kromhout D., Aravanis C., et al., Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study [published erratum appears in Arch. Intern. Med., 1995; 155(11): 1184], Arch. Intern. Med., 1995; 155: 381-6

  • Knekt P., Jarvinen R., Reunanen A., Maatela J., Flavonoid intake and coronary mortality in Finland: a cohort study, Brit. Med. J., 1996; 312: 478-81

  • Keli S. O., Hertog M. G., Feskens E. J., Kromhout D., Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study, Arch. Intern. Med., 1996; 156: 637-42

  • Yochum L., Kushi L. H., Meyer K., Folsom A. R., Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women, Am. J. Epidemiol., 1999; 149: 943-9

  • Schremm D. D., German J. B., Potential effects of flavonoids on the etiology of vascular disease, J. Nutr. Biochem., 1998; 9: 560-6

  • Yang T. T. C., Koo M. W. L., Inhibitory effect of Chinese green tea on endothelial cell-induced LDL oxidation, Atheriosclerosis, 2000; 148: 67-73

  • Miura Y., Chiba T., Miura S., et al., Green tea polyphenols (flavan 3-ols) prevent oxidative modification of low-density lipoproteins: An ex vivo study in humans, J. Nutr. Biochem., 2000; 11: 216-22

  • Hodgson J. M., Proudfoot J. M., Croft K. D., Puddey I. B., Mori T. A., Beilin L. J., Comparison of the effects of black and green tea on in vivo lipoprotein oxidation in human serum, J. Sci. Food Agric., 1999; 79: 561-6

  • Ishikawa T., Suzukawa M., Ito T., et al., Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification, Am. J. Clin. Nutr., 1997; 66: 261-6

  • Kono S., Shinchi K., Ikeda N., Yanai F., Imanishi K., Green tea consumption and serum lipid profiles: a cross-sectional study in northern Kyushu, Japan, Prev. Med., 1992; 21: 526-31

  • Frankel E., Activity of wine and grape phenolic antioxidants in human LDL, BioFactors, 1997; 6: 433-5

  • Kapiotis S., Hermann M., Held I., Seelos C., Ehringer H., Gmainer B. M., Genistein, the diatry-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL, Arterioscler. Thromb. Vasc. Biol., 1997; 17: 2688-74

  • Lichtenstein A. H., Soy protein, isoflavones, and cardiovascular disease risk, J. Nutr., 1998; 128: 1589-92

  • Marz-Demlow B. E., Duncan A. M., Wangen K. E., etal., Soy isoflavones improve plasm lipids in normocholesterolemic, premenopausal women, Am. J. Clin. Nutr., 2000; 71: 1462-9

  • Anthony M. S., Clarkson T. B., Williams J. K., Effects of soy isoflavones on atheriosclerosis: potential mechanisms, Am. J. Clin. Nutr., 1998; 68: 139S-3S

  • Chicchi L. M., Dietary phytoestrogens in the prevention of long-term postmenopausal diseases, Int. J. Gynecol. Obstet., 1999; 67: 39-40

  • Jenkins D. J. A., Kendall C. W. C., Garsetti M., et al., Effects of soy protein foods on low-density lipoprotein oxidation and ex vivo hormone receptor activity – A controlled crossover trail, Metabolism, 2ooo; 49: 537-43

  • Tikkanen M. J., Adlercreutz H., Dietary soy-derived isoflavone phytoestrogens – Could thez have a role in coronary heart disease orevention?, Biochemical Pharmacology, 2000; 60: 1-5

  • Wiseman H., O’Reilly J. D., Adlercreutz H., et al., Isoflavone phytoestrogens consumed in soy decrease F2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans, Am. J. Clin. Nutr., 2000; 72: 395-400

  • Pignatelli P., Pulcinelli F. M., Celestini A. et al., The flavonoids quarcetin and catechin synergistically inhibit platelet function by antagonizing the inracellular production of hydrogen peroxide, Am. J. Clin. Nutr., 2000; 72: 1150-5

  • Justenson U., Knuthsen P. Leth T., Determination of plant polyphenols in Danish foodstuffs by HPLC-UV and LC-MS detection, Cancer Letters, 1997; 114: 165-7

  • Dragsted L. O., Strube M., Leth T., Dietary levels of plant phenols and other non-nutritive components: Could they prevent cancer?, Eur. J. Cancer Prev., 1997; 6: 522-8

  • Linseisen J., Radtke J., Wolfram G., Flavonoidzufuhr Erwachsener in einem bayerischen Teilkollektiv der Nationalen Verzehrsstidie, Z. Ernahrungswiss., 1997; 36: 403-12

  • Ubbink J. B., Homocysteine – an atherogenic and a thrombogenic factor?, Nutr. Rev., 1995; 53: 323-5

  • McCully K. S., Chemical pathology of homocysteine. I., Atherogenesis Ann. Clin. Lab. Sci., 1993; 23: 477-93

  • Ubbink J. B., Vermaak W. J., Bennett J. M., Becker P. J., van Staden D. A., Bissbort S., The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease, Klin. Wochenschr., 1991; 69: 527-34

  • Wald N. J., Watt H. C., Law M. R., Wier D. G., McPartlin J., Scott J. M., Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention, Arch. Intern. Med., 1998; 158: 862-7

  • Arneson E., Refsum H., Bonaa K. H., Ucland P. M., Forde O. H., Nordrchaug J. E., Serum total homocysteine and coronary heart disease, Int. J. Epidemiol., 1995; 24: 704-9

  • Graham I. M., Daly L. E., Refsum H. M., et al., Plasma homocysteine as a risk factor for vascular disease, The Europen Concerted Action Project, JAMA, 1997; 277(22): 1775-81

  • Nygard O., Nordrchaug J. E., Refsum H., Ucland P. M., Farstad M., Vollset S. E., Plasma homocysteine levels and mortality in patients with coronary artery disease, N. Engl. J. Med., 1997; 337: 230-6

  • Brattström L., Zhang Y., Hurtig M., et al., A common gene mutation and longevity, Atherosclerosis, 1998; 141: 315-9

  • Folsom A. R., Nieto F. J., McGovern P. G., et al., Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 1998; 98: 204-10

  • Dierkes J., Krocsen M., Pietrzik K., Folic acid and vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women, Int. J. Vitam. Nutr. Res., 1998; 68: 98-103

  • Malonow M. R., Nieto F. J., Kruger W. D., et al., The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes, Arterioscler. Thromb. Vasc. Biol., 1997; 17: 1157-62

  • Ward M., McNulty H., McPartlin J., Strain J. J., Weir D. P., Scott J. M., Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid, Q. J. Med., 1997; 90: 519-24

  • Brönstrup A., Hages M., Pronz-Lagenohl R., Pietrzik K., Effects of folic acid and combinations of folic acid and vitamin B12 on plasma homocysteine concentrations in healthy, young women, Am. J. Clin. Nutr., 1998; 68: 1104-10

  • Brouwer I. A., van Duseldorp M., Thomas C. M. G., Duran M., et al., Low-dose folic acid supplementation decreases plasm homocysteine concentrations: a randomized trial, Am. J. Clin. Nutr., 1999; 69: 99-104

  • Durlach J., Bac P., Bara M., Guiet-Bara A., Cardiovasoprotective foods and nutrients: possible importance of magnesium intake, Magnes. Res., 1999; 12: 57-61

  • Laurant P., Touyz R. M., Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension, J. Hypertens., 2000; 18: 1177-91

  • Itoh K., Kawasaka T., Nakamura M., The effects of high oral magnesium supplementation on blood pressure, serum lipids, and related variables in apparently healthy Japanese subjects, Br. J. Med., 1997; 78: 737-50

  • Kawano Y., Matsuoka H., Takishita S., Omac T., Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures, Hypertension, 1998; 32: 260-5

  • Wirell M. P., Wester P. O., Stegmayr B. G., Nutritional dose of magnesium in hypertensive patients on beta-blockers lowers systolic blood pressure: A double-blind, crossover study, J. Intern. Med., 1994; 236: 189-95

  • Witteman J. C. M., Grobbec D. E., Derkx F. H. M., Bouillon R., De Bruijn A. M., Hofman A., Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension, Am. J. Clin. Nutr., 1994; 60: 129-35

  • Plum-Wirell M., Stegmayr B. G., Wester P. O., Nutritional magnesium supplementation does not change blood pressure nor serum or muscle potassium and magnesium in untreated hypertension, A double-blind crossover study, Magnes. Res., 1994; 7: 277-83

  • Sacks F. M., Willett W. C., Smith A., Brown L. E., Rosner B., Moore T. J., Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake, Hypertension, 1998; 31: 131-8

  • Shechter M.,, Merz C. N. B., Paul-Labrador M., et al., Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease, Am. J. Cardiol., 1999; 84: 152-6

  • Orlov M. V., Brodksy M. A., Bouban S., A review of magnesium, acute myocardial infarction and arrhythmia, J. Am. Coll. Nutr., 1994; 13: 127-32

  • Sasaki S., Oshima T., Matsuura H., et al., Abnormal magnesium status in patients with cardiovascular diseases, Clinical Science, 2000; 98: 175-81

  • Cappuccio F. P., Elliott P., Allender P. S., Pryer J., Follman D. A., Cutler J. A., Epidemiologic association between dietary calcium intake and blood pressure: A meta-analysis of published data, Am. J. Epidemiol., 1995; 142: 935-45

  • Lijnen P. Petrov V., Dietary calcium, blood pressure, and cell membrane cation transport system in males, J. Hypertens., 1995; 13: 875-82

  • Gillman M. W., Hood M. Y., Moore L. L., Nguyen U. S. D. T., Singer M. R., Andon M, B., Effect of calcium supplementation on blood pressure in children, J. Pediatr., 1995; 127: 186-92

  • Kawana Y., Yoshimi H., Matsuoka H., Takishita S., Omac T., Calcium supplementation in patients with essential hypertension: assessment by office, home, and ambulatory blood pressure, J. Hypertens., 1998: 16: 1693-9

  • Mccarron D. A., Reusser M. E., Finding concensus in the dietary calcium-blood pressure debate, J. Am. Coll. Nutr., 1999; 18: 398S-405S

  • Griffith L. E., Guyatt G. H., Cook R. J., Bucher H. C., Cook D. J., The influence of dietary and nondietary calcium supplementation on blood pressure – An updated meta-analysis of randomized controlled trials, Am. J. Hypertens., 1999; 12: 84-92

  • Durlach J., Bac P., Durlach V., Rayssiguier Y., Bara M., Guiet-Bara A., Magnesium status and aging: An update, Magnes. Res., 1998; 11: 25-42

  • Bronner F., Calcium and osteoporosis, Am. J. Clin. Nutr., 1994; 60: 831-6

  • Teegarden D., Weaver C. M., Calcium supplementation increases bone density in adolescent girls, Nutr. Rev., 1994; 52: 171-3

  • Lee W. T. K., Leung S. S. F., Leung D. M. Y., Tsang H. S. Y., Lau J., Cheng J. C. Y., A randomized double-blind controlled calcium supplementation trial, and bone and height acquisition in children, Br. J. Nutr., 1995; 74: 125-39

  • Welten D. C., Kemper H. C., Post G. B., van Staveren W. A., A meta-analysis of the effect of calcium intake on bone mass in young and middle-age females and males, J. Nutr., 1995; 125: 2802-13

  • Renner E., Dairy calcium, bone metabolism, and prevention of osteoporosis, J. Dairy Sci., 1994; 77: 3498-505

  • Reid I. R., Ames R. W., Evans M. C., Gamble G. D., Sharpe S. J., Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women; a randomized controlled trial, Am. J. Med., 1995; 98: 331-5




  • 1   2   3   4   5


    ©absta.pl 2019
    wyślij wiadomość

        Strona główna